The Drug Update: Recent drug approvals, summer 2026 edition

Area of Science:

• Pharmacology and Therapeutics
• Primary Care Medicine
• Drug Approval and Regulation

Background:

• The landscape of pharmacotherapy is continually evolving with new drug approvals.
• Primary care physicians require timely updates on novel medications and expanded indications for existing treatments.
• Regulatory agencies like the US Food and Drug Administration (FDA) play a crucial role in evaluating and approving new therapeutic agents.

Purpose of the Study:

• To inform primary care practitioners about significant new drug approvals in the latter half of 2025.
• To review newly approved indications for select existing medications relevant to primary care settings.
• To provide a concise overview of key pharmaceutical advancements impacting clinical practice.

Main Methods:

• Review of US FDA drug approval announcements from the second half of 2025.
• Identification of new molecular entities and new indications for existing drugs.
• Categorization of approved therapies based on their relevance to primary care practice.

Main Results:

• Approval of three novel medications: brensocatib (Brinsupri), elinzanetant (Lynkuet), and zoliflodacin (Nuzolvence).
• New indications granted for finerenone (Kerendia) in heart failure (left ventricular ejection fraction >_ 40%).
• New indications granted for cyclobenzaprine hydrochloride sublingual tablets (Tonmya) for fibromyalgia management.

Conclusions:

• Several new drugs and expanded indications were approved by the FDA in late 2025, offering new treatment options for primary care.
• Practitioners should familiarize themselves with these advancements to optimize patient care and therapeutic strategies.
• Ongoing monitoring of FDA approvals remains essential for evidence-based primary care.